AMENDMENT TO THE BIOPHARMACEUTICAL SERVICES AGREEMENTThe Biopharmaceutical Services Agreement • May 9th, 2012 • Synageva Biopharma Corp • Biological products, (no disgnostic substances)
THIS AMENDMENT (“Amendment”) effective as of April 27, 2012 (“Effective Date”), is between Synageva BioPharma Corp., a Delaware corporation with a principal office at 128 Spring Street, Suite 520, Lexington MA 02421 (phone: 781-357-9900; fax: 781-357-9901) (“Synageva”) and Cytovance Biologics, Inc. a Delaware corporation having its principal place of business at 800 Research Parkway, Suite 200 Oklahoma City, OK 73104 (“Cytovance”).
Cytovance Biologics, Inc. Biopharmaceutical Services Agreement for Synageva BioPharma Corp.Quality Agreement • May 9th, 2012 • Synageva Biopharma Corp • Biological products, (no disgnostic substances) • Massachusetts
This Biopharmaceutical Services Agreement (the “Agreement”) dated Feb. 27, 2012 (the “Effective Date”) between Synageva BioPharma Corp., (“Synageva”) a company having a place of business at 128 Spring Street, Suite 520, Lexington, MA 02421 and Cytovance Biologics, Inc. a Delaware corporation (“Cytovance”) having its principal place of business at 800 Research Parkway, Suite 200 Oklahoma City, OK 73104 (each a “Party”, collectively the “Parties”).
